Denali Therapeutics Inc.
NASDAQ Global SelectTotal Valuation
Denali Therapeutics Inc. carries a market capitalization of 3.93B, placing it among publicly traded companies globally. Its enterprise value stands at 2.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.93B |
| Enterprise Value | 2.44B |
Share Statistics
Denali Therapeutics Inc. currently has 158.66M shares outstanding.
| Shares Outstanding | 158.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.56 |
| P/TBV Ratio | 3.81 |
| P/FCF Ratio | -8.36 |
| P/OCF Ratio | -8.22 |
Financial Position
Denali Therapeutics Inc. maintains a current ratio of 9.28, meaning it holds 9.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.28 |
| Quick Ratio | 8.97 |
| Debt / Equity | 3.73 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -40.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Denali Therapeutics Inc.'s stock has gained approximately 81.8649% over the past 52 weeks. The 50-day moving average sits at 20.09, while the 200-day moving average is 18.41.
| Beta (5Y) | N/A |
| 52-Week Price Change | 81.8649% |
| 50-Day Moving Average | 20.09 |
| 200-Day Moving Average | 18.41 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -531.76M, while operating income came in at -547.12M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -547.12M |
| Pretax Income | -507.91M |
| Net Income | -508.02M |
| EBITDA | -531.76M |
| EBIT | -547.12M |
| Earnings Per Share (EPS) | -2.88 |
Balance Sheet
Denali Therapeutics Inc. holds 987.68M in cash and equivalents against 34.54M in total debt, resulting in a net debt position of -387.63M. Total book value stands at -2.18B, with working capital of 912.60M providing operational flexibility.
| Cash & Cash Equivalents | 987.68M |
| Total Debt | 34.54M |
| Net Debt | -387.63M |
| Equity (Book Value) | -2.18B |
| Book Value Per Share | -12.34 |
| Working Capital | 912.60M |
Cash Flow
Denali Therapeutics Inc. produced -412.34M in operating cash flow over the past twelve months. After subtracting -6.89M in capital expenditures, free cash flow totaled -419.23M - equivalent to -2.38 per share.
| Operating Cash Flow | -412.34M |
| Capital Expenditures | -6.89M |
| Free Cash Flow | -419.23M |
| FCF Per Share | -2.38 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.16 |
| FCF Yield | -11.96 |
Scores
Denali Therapeutics Inc. posts an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.92 |